Sean McCarthy, CytomX CEO

Cy­tomX halts lead pro­gram and will seek a part­ner as breast can­cer drug dis­ap­points

Mixed Phase II re­sults are forc­ing Cy­tomX to slam the brakes on one of its lead can­cer drugs — un­less it can con­vince a part­ner to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.